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This study investigated the prognostic significance of portal vein tumor thrombosis (PVTT) response in hepa-
tocellular carcinoma (HCC) patients treated with localized concurrent chemoradiotherapy (CCRT). We retro-
spectively analyzed 100 patients treated with CCRT for UICC Stage T2–4N0M0 HCC with PVTT between
2002 and 2011. The radiotherapy (RT) volume included both primary tumor and PVTT, and the median radi-
ation dose was 45 Gy. Treatment response was evaluated for up to 6 months after RT. With respect to PVTT
response to treatment, complete response (CR) and partial response (PR) were achieved in 14% and 48% of
patients, respectively, yielding an objective response (OR) rate of 62%. PVTT size (≤3cm diameter) was asso-
ciated with a higher rate of a CR (P = 0.001). The median overall survival (OS) was 11.6 months. Independent
prognostic factors for OS were OR of the tumor to RT and a CR of the PVTT. Achieving an OR in both the
tumor and the PVTT demonstrated a significant correlation with improved survival (P = 0.002). Progression of
intrahepatic metastasis was affected not by CCRT but by the clinical features of the PVTT, particularly the
initial PVTT site. PVTT response following CCRT seems prognostically significant. CR of the PVTT was
associated with improved survival. Achieving an OR in both the tumor and PVTT was also associated with
improved survival.
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response
INTRODUCTION
Tumor invasion into the portal vein by direct venous exten-
sion or metastasis occurs in up to 70% of patients with hepa-
tocellular carcinoma (HCC). Portal vein thrombosis appears
as a non-enhancing filling defect in the portal vein lumen on
computed tomography (CT), and can be classified as either
benign or malignant thrombosis. Tumors due to a malignant
portal vein tumor thrombosis (PVTT) tend to have larger dia-
meters than those due to a benign thrombosis. In many cases,
the PVTT is contiguous with the tumor as it frequently
occurs due to direct vascular invasion by the tumor [1].
HCC patients with PVTT have a poor prognosis, and early
recurrence of HCC and rapid development of intrahepatic
metastases are common in these patients. The median overall
survival (OS) duration has been reported to be approximately
three months for HCC patients with PVTT when untreated
[2]. Llovet et al. [3] found that a PVTT was an independent
prognostic factor for a reduced OS rate in HCC patients (odds
ratio, 1.9; 95% confidence interval, 1.2–2.9; P = 0.001).
The site of the PVTT influences the survival rate. The
mortality rate of patients with HCC is high, and the OS of
HCC patients with PVTT in the main trunk or first branch is†These authors contributed equally to this work.
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less than one year, with a tumor response rate after radiother-
apy (RT) of < 60% [4]. Ikai et al. [5] reported that the five-
year OS rate varied according to the PVTT site. The five-year
OS rates of HCC patients with PVTT at the second branch,
first branch and main portal trunk were 26%, 12% and 7%,
respectively.
Currently, standard of care for HCC with PVTT is recog-
nized as sorafenib. However, many treatments have been
attempted from the pre-sorafenib era [6]. Transcatheter arter-
ial chemoembolization (TACE) is considered in patients with
PVTT other than in the main or the first branch for fear of is-
chemic liver disease. External beam radiotherapy has also
been attempted. Yoon et al. [7] reported the clinical out-
comes of TACE and RT for HCC invading the portal vein
(PV), showing a tumor response rate of 27.6%, a PVTT
response rate of 39.6%, and a median survival of 10.6
months. Kim et al. [8] examined the outcomes of treatment
with radiation alone for HCC with PVTT, and reported a
considerable PVTT response rate of 45.8%, and a median
survival duration in responders of 10.7 months. In our
institute, intra-arterial (iA) 5-fluorouracil (5-FU) concurrent
chemoradiotherapy (CCRT) was used to treat HCC asso-
ciated with a PVTT before sorafenib was introduced. Han
and Seong et al. [9] reported that iA 5-FU CCRT resulted
in longer survival (median, 13.1 months). These reports
suggest that substantial regression of the PVTT can be
induced following radiotherapy. However, whether the
PVTT response can have prognostic significance in terms of
survival benefit has not been researched to date.
In this study, we investigated the prognostic significance
of the PVTT response to iA CCRT in patients in which both
HCC and a PVTT were present.
MATERIALS ANDMETHODS
Patients
One hundred HCC patients with PVTT who received radio-
therapy and iA concurrent chemotherapy at Severance
Hospital at the Yonsei University between April 2002 and
March 2011 were retrospectively analyzed. A diagnosis of
HCC was made according to the Korean Liver Cancer Study
group guidelines, either histologically or based on typical
radiologic findings of HCC using two dynamic imaging
studies (CT, magnetic resonance imaging, or hepatic angiog-
raphy) or one positive image finding with an elevated serum
alpha-fetoprotein (AFP) level of >200 ng/ml.
Modified criteria from the 6th International Union Against
Cancer (UICC) were used for staging, and patients staged
T2–4N0M0 were included in the present study. Patients with
Eastern Cooperative Oncology Group performance status
0–2 and Child–Pugh Stage A or B were included in the
current study. Patients who had received previous RT to the
abdomen and those who were diagnosed with intrahepatic
metastasis outside the RT field, regional lymph node
metastasis, or extrahepatic metastasis at the time of RT were
excluded. Patients who initially presented with multiple
intrahepatic metastases in both lobes of the liver and who
could not undergo localized treatment were also excluded
from analysis in the current study. However, when multiple
tumors were localized and could be included in the radiation
field, the patients were included. Patients who had portal
vein tumor thrombosis without the tumor component were
excluded.
Portal vein tumor thrombosis was confirmed as a filling
defect on the CT scan with complete occlusion of the vessel
lumen in the portal vein. A PVTT was also evaluated and
confirmed by MRI (51.0%), hepatic angiography (69.0%,
with thread and streak signs), and PET/CT (positron emis-
sion tomography/computed tomography, 72.0%).
Treatment
Prior to CT simulation, all patients underwent respiration
training to maintain regular breathing. Contrast-enhanced CT
was performed using a slice thickness of approximately 3–5
mm. The gross tumor volume (GTV) was defined as the
volume of the tumor visible on the planning CT or fused
magnetic resonance imaging. Salvage or curative aim radio-
therapy was given; the radiation target volume included all
sites of residual disease and previously treated lesions. All of
the viable tumors in the liver and PVTT were included in the
GTV. The clinical target volume (CTV) was defined as the
GTV plus a 0.5-cm margin. All cases of PVTT were continu-
ous with the main tumor and there were no cases of thrombi
without the tumor component. There were no cases of PVTT
without continuum with the tumor in patients with multifocal
PVTT. Diaphragm movement was checked using a fluoro-
scope and was incorporated when defining the internal target
volume (ITV). Since 2010, we have used 4D CT to set the
ITV according to respiration. The planning target volume
(PTV) was defined by adding a 0.5-cm margin to the ITV,
and a 0.7-cm block margin was added. Patients were treated
with 3D conformal RT (72 patients) and helical tomotherapy
(28 patients; Madison, WI, USA). Because a higher RT dose
was recommended for a response [8], patients were selected
with a cumulative dose ≥45 Gy in the present study. The
median total dose was 45.0 Gy (range, 45.0–60.0 Gy), deliv-
ered in a fractional dose of 1.8–3.0 Gy. Most patients who
were treated with 3D conformal RT received a total dose of
45 Gy in 25 fractions. For patients treated with helical
tomotherapy, the simultaneous integrated boost technique
was applied, and most patients received 50 Gy to the GTV
and 45 Gy to the CTV delivered in 20 fractions. The median
total biologic effective dose (BED) was 53.1 Gy10 (range,
53.1–78.0 Gy10). For radiation treatment planning, the entire
liver, except for the CTV, was defined as the remaining liver,
and we kept this volume greater than 800 ml. The mean dose
to the remaining liver was kept under 26 Gy, and the volume
of the remaining liver receiving over 30 Gy (V30) was less
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than 60% [10, 11]. For the dose constraint for normal organs
such as the stomach and duodenum, we kept the volume to
receive over 45 Gy to less than 2 ml. Additionally, for the
heart, we set the mean dose to less than 26 Gy and 30% of
the volume to receive less than 45 Gy. For the kidneys, we set
the equivalent dose for at least one kidney to less than 20 Gy.
For all patients, intrahepatic arterial infusion of 5-
fluorouracil (iA 5-FU) was delivered (500 mg/day) during
the first and last weeks of RT. One month after RT, a portion
(18%) of patients received iA 5-FU (500 mg/m2) and cis-
platin (60 mg/m2) every 4 weeks for 3–12 cycles according
to the response [9].
Response evaluation
The results of treatment were evaluated using CT or MRI
one month after RT and at three to six months during follow
up. The treatment response at six months after RT showed
the maximum response and was used to define the treatment
response.
For the evaluation of the tumor response, the modified
Response Evaluation Criteria in Solid Tumors were used
[12]. For evaluation of the PVTT response, the patients were
divided into four groups: complete response (CR: complete
disappearance, patency), partial response (PR: >50% de-
crease in the thrombus diameter), stable disease (SD: <50%
decrease or <25% increase in the thrombus diameter or cav-
ernous transformation), and progressive disease (PD: >25%
increase in the thrombus diameter or newly developed
PVTT) based on the criteria described by Yoon et al. [7] and
Huang et al. [13]. Cavernous transformation of PVTT was
considered SD since it may not be a direct effect of RT. The
objective response (OR) rate was defined as the percentage
of patients whose tumor shrank or disappeared (CR + PR)
after RT.
The size of the tumor or PVTT was based on the
maximum diameter in the axial cut of CT or MRI before
treatment. The sum of the longest diameters of multiple
lesions was used for response evaluation of multifocal
lesions.
According to the modified UICC criteria, the PVTT sites
were classified as follows: main trunk (portal venous inva-
sion in the main portal vein), first branch (portal venous in-
vasion in the lobar branch), and below the second branch
(portal venous invasion in the subsegmental branch and
portal venous invasion in the lower portion of the subseg-
mental branch). Concerning multiple PVTT, a previous
study showed that the prognosis was better when the site of
tumor thrombosis was peripheral rather than central in the
order of the second branch, first branch and main trunk [13].
Therefore, categorization was based on the central lesion that
determined prognosis.
Toxicities were evaluated for patients who received RT
using the Radiation Therapy Oncology Group (RTOG) tox-
icity scale.
Statistics
SPSS® version 18 was used for statistical analysis. The chi-
square test and Fisher’s exact test were used to identify the
correlations between the tumor and PVTT responses and
various factors. To identify the correlation between PVTT
size (axial diameter) and treatment response, binary logistic
regression was used. For analysis of survival rate, the
Kaplan–Meier method was used for univariate analysis and
the Cox proportional hazards model was used for multivari-
ate analysis.
RESULTS
Patient characteristics
The median follow-up period for all patients was 9.7 months.
All patients were treated for both the tumor and the PVTT.
Table 1 describes the clinical characteristics of the patients.
The median age of the patients was 55 years, and 88.0%
were males. Out of 100 patients, 84 (84.0%) had viral hepa-
titis B, 8 (8.0%) had viral hepatitis C, and 8 (8.0%) had
non-B, non-C hepatitis. The main site (82.0%) of PVTT was
the main trunk or the first branch. Four of the patients with
PVTT in the main trunk had a tumor thrombus in the inferior
vena cava (IVC). IVC thrombus was included in the target
volume in all of the four patients (categorized to PVTT in the
main trunk since all of them had main portal vein thrombus
concurrently). The median PVTT size was 4.4 cm. Of the
100 patients, 70 (70.0%) had a single tumor, and 30 (30.0%)
had multiple tumors (pre-treatment intrahepatic metastasis
within the area of RT); 16 (16.0%) had a tumor size of < 5
cm, 43 (43.0%) had a tumor size between 5 and 10 cm, and
41 (41.0%) had a tumor size > 10 cm (median tumor size, 9
cm). There were 12 T2N0 patients enrolled who had inad-
equate liver function for TACE or vascular invasion. The
AFP level was < 400 ng/ml in 38 patients (38.0%),
and > 400 ng/ml in 62 patients (62.0%). Treatment with
another modality prior to CCRT had been administered to 30
patients (30.0%); 28 (28.0%) of the patients had been treated
with TACE before CCRT, and five of these had received
TACE on the area of RT within a month of CCRT. After one
month of CCRT, 18 patients (18.0%) had undergone adju-
vant intra-arterial chemotherapy according to the response
and hepatic function.
Response analysis
In terms of tumor response, the numbers of patients who
showed CR, PR, SD and PD were 0 (0%), 41 (41.0%), 20
(20.0%) and 39 (39.0%), respectively. The OR rate was
42.0%. In terms of PVTT response, the numbers of patients
with CR, PR, SD and PD were 14 (14.0%), 48 (48.0%), 29
(29.0%) and 9 (9.0%), respectively. PVTT response rate (OR
62.0%) was higher than tumor response rate (OR 41.0%).
Table 2 shows PVTT and tumor response rates. Of the
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patients who had a tumor OR (CR + PR, n = 41), six
achieved CR of PVTT. The median period for the PVTT to
show a response was 0.91 month. A borderline correlation
was found between the objective PVTT response rate
(CR + PR) and the tumor response rate (CR + PR) at six
months (P = 0.055 by chi-square test, P = 0.063 by Fisher’s
exact test). A statistically significant correlation was noted
between CR of PVTT and PVTT size, showing a higher rate
of CR for PVTT < 3cm (P = 0.001, by Fisher’s exact test).
There was a dose–response relationship between higher ra-
diation dose [8] and increased tumor response (BED > 58
Gy10, P = 0.006, by chi square test). However, increase in ra-
diation dose did not result in improved response in PVTT
(P = 0.286).
Survival and prognostic factors
The median OS was 11.6 months. The 1-year survival rate
was 46.8%, and the 2-year survival rate was 21.9%. The
median tumor progression-free survival was 8.2 months,
and the median PVTT progression-free survival was 10.3
months.
Univariate analysis showed that the factors affecting the
OS rate included the OR of tumor (CR + PR; P = 0.007),
AFP level (>400 ng/ml, P = 0.010), tumor size ( > 10 cm,
P = 0.027) and a CR of the PVTT (P = 0.048) (Table 3).
Figure 1 shows that a CR of the PVTT is associated with
improved OS (P = 0.043). OS was not affected by TACE
before CCRT (P = 0.685). Multiplicity of the primary tumor
(pre-existing intrahepatic metastasis within the RT field) was
not associated with survival outcome (P = 0.555). In add-
ition, progression of intrahepatic metastasis after CCRT
showed no relationship to survival outcome (P = 0.832).
Multivariate analysis showed that independent prognostic
factors for OS were an OR of the tumor (CR + PR;
Table 2. Response of tumor and portal vein tumor
thrombosis
Response
No. of patients
with tumor
responses (%)
No. of patients
with PVTT
responses (%)
Complete response (CR) 0 (0%) 14 (14.0%)
Partial response (PR) 41 (41.0%) 48 (48.0%)
Stable disease (SD) 20 (20.0%) 29 (29.0%)
Progressive disease (PD) 39 (39.0%) 9 (9.0%)
Objective response
(CR + PR)
41 (41.0%) 62 (62.0%)
PVTT = portal vein tumor thrombosis. A borderline
correlation was found between the 6-months objective
response rates (CR + PR) of PVTT and the tumor.
Table 1. Characteristics of patients, tumors and PVTT
Characteristics
Total (n = 100)
No. %
Gender
M 88 (88.0)
F 12 (12.0)
Age (years)
mean 55
range 30–84
Viral etiology
HBsAg (+) 84 (84.0)
HBsAg (−) 16 (16.0)
Child Pugh class
A 93 (93.0)
B 7 (7.0)
AFP (ng/ml)
≤400 38 (38.0)
>400 62 (62.0)
Tumor maximum diameter
in axial CT (cm)
≤5 16 (16.0)
5–10 43 (43.0)
>10 41 (41.0)
Tumor multiplicity
single 70 (70.0)
multiple 30 (30.0)
Modified UICC T stage
T2 12 (12.0)
T3 63 (63.0)
T4 25 (25.0)
PVTT main site
Main trunka 38 (38.0)
1st branch 44 (44.0)
2nd branch 18 (18.0)
PVTT maximum diameter
in axial CT (cm)
≤3 18 (18.0)
>3 82 (82.0)
CT = computed tomography, UICC = International Union
Against Cancer, AFP = alpha feptoprotein, PVTT = portal vein
tumor thrombosis. aFour patients concurrently had inferior
vena cava tumor thrombosis.
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P = 0.005) and a CR of the PVTT (P = 0.041; Table 2).
Neither high level of AFP (>400 ng/ml) nor tumor size (>10
cm) affected OS in multivariate analysis.
The patients were stratified into four groups according to
the PVTT and tumor OR (CR + PR) and analyzed for differ-
ence in OS (Fig. 2). The group that showed a response both
in PVTT and tumor had the longest OS (n = 30; median, 16.7
months), which contrasted with the OS in the group that
showed response neither in tumor nor in PVTT (n = 27;
median, 8.4 months). The OS difference in the two groups
was statistically significant (P = 0.002, Log rank test). The
OS in other groups, one showing a response in the tumor
alone (n = 11; median, 16.0 months) and the other showing a
response in the PVTT alone (n = 32; median, 11.4 months)
were similar.
Among patients with a PVTT in the main trunk or first
branch (n = 82), the median OS was 10.6 months and the OS
rate tended to be increased in patients who achieved OR of
the PVTT (n = 52, P = 0.017, median OS, 11.9 months vs
7.7 months, Fig. 3). The median OS in patients with a PVTT
in the subsegmental branch (n = 18) was 19.1 months, and
the OR of the PVTT was not associated with survival im-
provement (P = 0.828) for these patients.
Table 3. Prognostic factor influencing overall survival
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
T stage (UICC Stage T4) 0.861 (0.471–1.574) 0.626
Tumor size (maximum axial diameter > 10 cm) 1.683 (1.060–2.671) 0.027 1.393 (0.860–2.256) 0.178
AFP (>400 ng/ml) 1.913 (1.171–3.126) 0.010 1.402 (0.827–2.375) 0.209
PVTT site (main + 1st branch) 1.271 (0.669–2.416) 0.464
PVTT size (maximum axial diameter > 3 cm) 1.204 (0.671–2.160) 0.534
Tumor objective response (CR + PR) 1.984 (1.210–3.254) 0.007 2.090 (1.251–3.487) 0.005
PVTT objective response (CR + PR) 1.580 (0.990–2.522) 0.055
PVTT complete response (CR) 0.475 (0.227–0.994) 0.048 0.445 (0.205–0.968) 0.041
HR = hazard ratio; CI = confidence interval; AFP = alpha feptoprotein; PVTT = portal vein tumor thrombosis;
CCRT = concurrent chemoradiotherapy; UICC = International Union Against Cancer; CR = complete response;
PR = partial response.
Fig. 1. Overall survival according to response status following
PVTT (P = 0.048, by log-rank test). The solid line represents
patients who achieved a CR (n = 14), and the dotted line represents
those who did not achieve a CR (n = 86; PR + SD + PD).
Fig. 2. Overall survival (OS) of four patient groups according to
the tumor and PVTT response (CR + PR). The group that showed a
response both in PVTT and tumor had the longest OS (n = 30;
median, 16.7 months), which contrasted to OS in the group that
showed response neither in tumor nor in PVTT (n = 27; median, 8.4
months). The OS difference in the two groups was statistically
significant (P = 0.002, Log rank test), The OS in other groups, one
showing a response in the tumor alone (n = 11; median, 16.0
months) and the other showing a response in the PVTT alone
(n = 32; median, 11.4 months) was similar.
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There was no survival benefit from increased radiation
dose (BED > 58 Gy10, P = 0.624).
Progression of intrahepatic metastasis related
to a PVTT
Intrahepatic metastasis is frequently associated with a PVTT.
We analyzed its progression (occurrence or dissemination of
intrahepatic metastasis) in relation to clinical features of the
PVTT as well as to the tumor response after CCRT.
Regarding clinical features of the PVTT, 20% of patients
with a PVTT size < 3 cm showed intrahepatic metastasis,
whereas 42.5% of patients with a PVTT size > 3 cm showed
newly developed intrahepatic metastasis (Table 4). When the
PVTT site was the main trunk or the first branch, the occur-
rence of intrahepatic metastasis was significantly higher
(42.7%) than when the second branch was involved (16.7%).
Regarding tumor response after CCRT, CR of the PVTT
showed a statistically significant correlation with lower pro-
gression of intrahepatic metastasis (P = 0.049 by chi-square
test, P = 0.073 by Fisher’s exact test). The OR (CR + PR) of
the PVTT showed no correlation (P = 0.812 by chi-square
test, P = 0.835 by Fisher’s exact test).
Toxicity
As for adverse effects during treatment, four patients experi-
enced elevation of alanine aminotransferase (one patient
with Grade 2 and three patients with Grade 3). Eight patients
experienced thrombocytopenia (one patient was Grade 1,
five patients were Grade 2 and two patients were Grade 3).
Five patients developed leukocytopenia (three patients were
Grade 2, and two patients were Grade 3) during CCRT.
As for late toxicity after treatment ( > 3 months later), 29
patients experienced gastroduodenitis. Of these, one died of
upper gastrointestinal bleeding. In addition, three patients
Fig. 3. Overall survival according to overall response (OR) of
patients with PVTT located in the main and first branch of the
portal vein (P = 0.017). The solid line represents patients who
achieved an OR (CR + PR, n = 52) and the dotted line represents
those who did not achieve an OR (n = 30).
Table 4. Progression of intrahepatic metastasis according to clinical features and treatment
response of PVTT
Intrahepatic metastasis
No Yes
Variable No. (%) No. (%) Total P-valuea
PVTT size 0.064b
≤3 cm 16 (80.0) 4 (20.0) 20
>3 cm 46 (57.5) 34 (42.5) 80
PVTT site 0.039c
main & 1st branch 47 (57.3) 35 (42.7) 78
2nd branch 15 (83.3) 3 (16.7) 18
PVTT response to CCRT
CR 12 (85.7) 2 (14.3) 14 0.049d
No CR 50 (58.1) 36 (41.9) 86
CR + PR 39 (62.9) 23 (37.1) 62 0.056
SD + PD 23 (60.5) 15 (39.5) 38
PVTT = portal vein tumor thrombosis. aP-value calculated by chi-square test in this table.
bP = 0.075 by Fisher’s exact test. cP = 0.059 by Fisher’s exact test. dP = 0.073 by Fisher’s
exact test.
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experienced symptomatic radiation pneumonitis and two
patients experienced non-symptomatic radiation pneumon-
itis. One patient was admitted and treated with intravenous
antibiotics and prednisolone, and another patient was treated
with oral prednisolone. Symptoms of patients were relieved
by conservative treatment with prednisolone. Four patients
who experienced radiation pneumonitis had tumors in the
right upper lobe of the liver.
Pattern of failure
Progression of intrahepatic metastases occurred in 38
patients, and 37 patients showed metastases to distant organs
after CCRT. The lungs were the most common site of distant
failure (24 patients).
Death occurred in 73 patients throughout the observed
periods, the major cause being hepatic failure (n = 40).
Incidence of death from hepatic failure was higher in patients
with huge primary tumors (>10 cm, P = 0.021 by chi-square
test, P = 0.035 by Fisher’s exact test) and lower in patients
with a CR of the PVTT after CCRT (P = 0.013 by chi-square
test, P = 0.013 by Fisher’s exact test). Neither OR of tumor
nor intrahepatic metastases were associated with death due to
liver failure.
Long-term survival analysis
There were 14 patients who lived longer than two years after
CCRT. As a common clinical feature, 12 among them had
initially a single tumor; all patients had tumors < 10 cm.
After CCRT, two patients underwent surgical resection, and
one patient underwent liver transplantation. Three patients
received TACE after CCRT.
DISCUSSION
Our study showed that CCRT could induce a substantial re-
sponse in the PVTT. The PVTT response rate (OR, 62.0%) was
higher than the tumor response rate (OR, 41.0%). This could be
explained by tumor burden; PVTTs tended to be smaller than
tumors (median size of PVTT, 4.4 cm vs tumor 9 cm). We also
showed that CR of the PVTT was associated with improved
survival. A higher CR rate was achieved when the PVTT was
smaller (≤3 cm), which significantly increased the OS.
A PVTT affects the vascular supply of the liver, thus influ-
encing the overall liver function. Resolution of the PVTT
after RT can restore the interrupted portal venous flow,
hence maintaining oxygenation and function of the liver.
Therefore, the PVTT response could affect survival in a dif-
ferent way to that of the tumor response. In this study,
patients achieving an OR in both the PVTT and the tumor
showed the best outcomes (P = 0.002, Fig. 2). Tumor throm-
bus location influenced the outcome of radiotherapy in HCC
with vascular invasion [14]. In the present study, most of the
patients (82.0%) had a PVTT in the main trunk and the first
branch, the sites known to be associated with a poor
prognosis [15]. Compared with a PVTT at other sites, when
the PVTT site is the main trunk or first branch there is a
greater likelihood of portal hypertension, which can in turn
cause impairment of liver function and hence lowering of the
survival rate [15]. Of the patients with a PVTT in the main
trunk or first branch (n = 82), a PVTT OR was achieved in 52
patients (63.4%); the OS rate increased significantly
(P = 0.017, Fig. 3) in patients with OR. It seems that the risk
of poor outcome associated with proximal PVTT location can
be overcome by radiotherapy. Toyosaka et al. [16], hypothe-
sized that occurrence of tumor thrombi is due to the portal
veins working as efferent vessels in HCC, and reported a sig-
nificant correlation between a PVTT and the presence of intra-
hepatic metastasis. Intrahepatic metastasis was considered a
poor prognostic factor in HCC patients [17]. Reports of intra-
hepatic dissemination after radiofrequency ablation (RFA) and
local ablation have been published [18, 19]. Ruzzenente et al.
[18] indicated risk factors involving AFP level (>200 kU/l),
location of the tumor (<1 cm from primary or sectional portal
branches) and histological differentiation.
In practice, clinicians used to worry that radiotherapy, a
potent antitumor agent, might promote intrahepatic metasta-
sis from a PVTT. In this study, we analyzed the occurrence
of intrahepatic metastasis according to clinical features and
outcome following CCRT. Our results clearly showed that
intrahepatic metastasis was affected not by RT but by the clin-
ical features of the PVTT, particularly the initial PVTT site.
For the patient population in this study, with both HCC
and a PVTT, the standard treatment recommended today is
sorafenib. Sorafenib was introduced to Korea in 2009, and
national health insurance coverage for this treatment began
in 2011. Therefore, our patients, who were treated between
2002 and 2011, did not have the option of treatment with sor-
afenib. In a previous study our group has reported the results
of a pilot trial in which 40 HCC patients with PVTT received
iA 5-FU chemotherapy along with RT [9]. The tumor re-
sponse rate was 45%, and the median survival duration was
13.1 months from the start of RT, representing the longest
survival duration in the reported results of CCRT for HCC
with a PVTT. However, the study included patients with ad-
equate liver function (indocyanine green retention rate at 15
minutes after dye loading, <20%; Child Pugh A), and
patients with multifocal and bilobal involvement were
excluded. In the present study, patients with more negative
prognostic factors (salvage treatment, 30%) were included
compared with previous studies, explaining the slightly
reduced median survival time (median OS, 11.6 months).
CONCLUSION
The PVTT response following CCRT appears to be prognostic-
ally significant. Complete response of a PVTT was associated
with improved survival. Achieving an OR in both the tumor
and the PVTTwas also associated with improved survival.
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